Kiromic Biopharma Inc (KRBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has a cash flow conversion efficiency ratio of 0.290x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.65 Million) by net assets ($-12.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KRBP net asset quality score to measure how much of total assets are equity-financed.
Kiromic Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore KRBP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Kiromic Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiromic Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TRELLUS HEALTH LS -0006
F:85Q
|
N/A |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
0.000x |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
-0.046x |
|
Investor Centre Ltd
AU:ICU
|
0.119x |
|
IXICO PLC
LSE:IXI
|
-0.118x |
|
TEVANO SYSTEMS HLDGS INC.
F:7RBA
|
N/A |
|
Springer Nature AG & Co KGaA
XETRA:SPG
|
N/A |
|
NAHL Group PLC
LSE:NAH
|
0.154x |
Annual Cash Flow Conversion Efficiency for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kiromic Biopharma Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Kiromic Biopharma Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.59 Million | $-19.46 Million | 1.546x | -33.57% |
| 2023-12-31 | $-9.12 Million | $-21.23 Million | 2.327x | -43.41% |
| 2022-12-31 | $-5.77 Million | $-23.75 Million | 4.112x | +652.82% |
| 2021-12-31 | $27.32 Million | $-20.32 Million | -0.744x | -37.95% |
| 2020-12-31 | $11.36 Million | $-6.13 Million | -0.539x | +63.38% |
| 2019-12-31 | $1.98 Million | $-2.91 Million | -1.472x | +81.86% |
| 2018-12-31 | $265.30K | $-2.15 Million | -8.115x | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more